Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating

Related Keywords

Italy ,United States ,Highbridge ,Somerset ,United Kingdom ,Spain ,Pratteln ,Switzerland General ,Switzerland ,France ,Austria ,China ,Germany ,German ,America ,French ,Swiss ,Shabir Hasham ,Dario Eklund ,Andrew Smith ,Eva Kalias ,Chiesi Farmaceutici ,America To Catalyst Pharmaceuticals Inc ,Life Science Alliance ,National Institute For Health ,Santhera Pharmaceuticals Holding ,Catalyst Pharmaceuticals Inc ,Nasdaq ,Exchange Regulation Ltd ,Regulatory Agency ,Santhera Pharmaceuticals Holding Ltd ,Drug Administration ,Chiesi Group ,European Medicines Agency ,Bonds ,European Union Summary Of Product Characteristics ,Exchange Regulation ,Catalyst Pharmaceuticals ,Head Investor Relations Communications ,China National Medical Products Administration ,Santhera Pharmaceuticals ,Announces Preliminary Unaudited ,Provides Corporate Update Ahead ,Full Report Publication ,North America ,Drug Evaluation ,National Medical Products Administration ,National Institute ,Care Excellence ,Sperogenix Therapeutics ,Annual General Meeting ,Regulation Ltd ,United States Prescribing Information ,European Union Summary ,Proc Natl Acad Sci United States ,Head Investor Relations ,Convertible Bonds ,Santhera ,